Tc-99m MIBI SPECT is useful for noninvasively predicting the presence of MDR1 gene-encoded P-glycoprotein in patients with hepatocellular carcinoma

Clinical Nuclear Medicine

Volumn 24, Issue 11, 1999, Pages 874-879

  Young, Soo Kim ^a   Sung, Won Cho ^a   Kwang, Jae Lee ^a   Ki, Baik Hahm ^a   Hee, Jung Wang ^a   Yim, Hyunhee ^a   Youn, Mi Jin ^a   Chan, Hee Park ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Hepatocellular Carcinoma; Multidrug Resistance; P glycoprotein; Tc 99m MIBI SPECT

Indexed keywords

ANTINEOPLASTIC AGENT; AVIDIN; BIOTIN; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; PEROXIDASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LIVER BIOPSY; LIVER CELL CARCINOMA; MALE; MULTIDRUG RESISTANCE; PREDICTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032746515     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-199911000-00011     Document Type: Article

References (42)

1. Gottesman MM: Multidrug resistance during chemical carcinogenesis: A mechanism revealed. J Natl Cancer Inst 80:1352, 1988.
2. Huang C, Mengchao W, Xu G, et al: Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84:262, 1992.
3. Ford JM, Hait W: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155, 1990.
4. Roninson IB, Chin JE, Choi KG, et al: Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A 83:4538, 1986.
5. Kabasakal L, Ozker K, Hayward M, et al: Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance. Eur J Nucl Med 3:568, 1996.
6. Park J, Lee S, Hong I, et al: MDR1 gene expression: Its effect on drug resistance to doxorubicin in hepatocellular carcinoma cell lines. J Natl Cancer Inst 86:700, 1994.
7. Goldstein L, Galski H, Fojo A, et al: Expression of multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116, 1989.
8. Itsubo M, Ishikawa T, Toda G, et al: Immunohistochemical study of expression and cellular localization the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer 73:298, 1994.
9. Rothenberg M, Ling V: Multidrug resistance: Molecular biology and clinical relevance. J Natl Cancer Inst 81:907, 1989.
10. Yeh GC, Lopeczynska J, Poore CM, et al: The new functional role for P-glycoprotein: Efflux pump for benzo(a)pyrene in human breast cancer MCF-7 cells. Cancer Res 52:6692, 1992.
11. Kurelec B, Pivevic B: Evidence for multixenobiotic resistance mechanism in the mussel mytilus galloprovincialis. Aquatic Tox 19:291, 1991.
12. Dunn SE, Hughes CS, LeBalanc GA, et al: Overexpression of a P-glycoprotein in hepatocellular carcinomas from woodchuck hepatitis virus-infected woodchucks (Maarmota monax). Hepatology 23:662, 1996.
13. Muller S, Guth-Tougelides B, Creutzig H: Imaging of malignant tumors with Tc-99m MIBI SPECT. J Nucl Med 28:562, 1987.
14. Hassan IM, Sahweil A, Constantinides C, et al: Uptake and kinetics of Tc-99m-hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 14:333, 1989.
15. Piwnica-Worms D, Holman BL: Noncardiac applications of hexakis (alkylisonitrile) technetium-99m complexes. J Nucl Med 31:1166, 1990.
16. Caner B, Kitapci M, Aras T, et al: Increased accumulation of hexakis (2-methoxy isobutyl isonitrile) technetium (I) in osteosarcoma and its metastatic lymph nodes. J Nucl Med 32:1977, 1991.
17. Caner B, Kitapci M, Erbengi G, et al: Increased accumulation of Tc-99m MIBI in undifferentiated mesenchymal tumor and its metastatic lung lesions. Clin Nucl Med 17:144, 1992.
18. Tirovola EB, Biassoni L, Britton KE, et al: The use of Tc-99m MIBI scanning in multiple myeloma. Br J Cancer 74:1815, 1996.
19. Derebek E, Kirkali Z, Dogan S, et al: Tc-99m MIBI scintigraphy in metastatic renal cell carcinoma: Clinical validation of the relationship between Tc-99m MIBI uptake and P-glycoprotein expression in tumor tissue. Eur J Nucl Med 23:976, 1996.
20. Kostakoglu L, Elahi N, Kiratli P, et al: Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J Nucl Med 38:1003, 1997.
21. Piwnica-Worms D, Chiu ML, Budding M, et al: Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:977, 1993.
22. Batist G. Tulpule A, Sinha BK, et al: Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 261:15554, 1986.
23. Rao VV, Chiu ML, Kronauge JF, et al: Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 35:510, 1994.
24. Piwnica-Worms D, Kronauge JF, Chiu ML: Uptake and retention of hexakis (2-methoxy isobutyl isonitrile) technetium (I) in cultured chick myocardial cells: Mitochondrial and plasma membrane potential dependence. Circulation 82:1826, 1990.
25. Fairchild CR, Ivy SP, Rushmore T, et al: Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocelluar carcinomas. Proc Natl Acad Sci U S A 84:7701, 1987.
26. Thorgeirsson SS, Huber BE, Sorrell S, et al: Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 236:1120, 1987.
27. Woo A, Tsao MS, Batist G: Drug resistance in cultured rat liver epithelial cells spontaneously and chemically transformed. Carcinogenesis 13:1675, 1992.
28. Gottesman MM, Willingham MC, Pastan I: Expression of the MDR1 gene in normal human tissue. In: Roninson IB, ed. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York: Plenum Press, 1991, pp 279-90.
29. Gottesman MM, Goldstein LJ, Foja A: Expression of the multidrug resistance gene in human cancers. In: Roninson IB, ed. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York: Plenum Press, 1991, pp 291-302.
30. Nagasue N, Dhar DK, Makino Y, et al: Overexpression of P-glycoprotein in adenomatlus hyperplasia of human liver with cirrhosis. J Hepatol 22:197, 1995.
31. Soini Y, Virkajarvi N, Raunio H, et al: Expression of P-glycoprotein in hepatocellular carcinoma: A potential marker of prognosis. J Clin Pathol 49:470, 1996.
32. Ross DD, Thompson BW, Ordonez JV, et al: Improvement of flow-cytometric detection of multidrug-resistant cells by cell-volume normalization of intracellular daunorubicin content. Cytometry 10:185, 1989.
33. Lampidis TJ, Castello C, del Giglio A, et al: Relevance of the chemical charge of rhodamine dyes to multiple drug resistance. Biochem Pharmacol 38:4267, 1989.
34. Chan H, Thorner P, Haddad G, et al: Immunohistochemical detection of p-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689, 1990.
35. Kessel D, Beck WT, Kukuruga D, et al: Characterization of multidrug resistance by fluorescent dyes. Cancer Res 51:4665, 1991.
36. Noonan KE, Beck C, Holzmayer TA, et al: Quantitative analysis of MDR (multidrug-resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A 87: 7160, 1990.
37. Cordon-Cardio C: Immunohistochemical analysis of P-glycoprotein expression in normal and tumor tissues in humans. In: Roninson IB, ed. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York: Plenum Press, 1991, pp 303-16.
38. Charpin C, Vielh P, Duffaud F, et al: Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: Correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 86:1539, 1994.
39. Cordobes MD, Starzes A, Delmon-Moingeon L, et al: Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: Correlation with mdr gene expression. J Nucl Med 37:286, 1996.
40. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, et al: Evaluation of tumor metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 22:434, 1995.
41. Ciarmiello A, Del Vecchio S, Potena MI, et al: Technetium-99m-sestamibi efflux and P-glycoprotein expression in human breast carcinoma [Abstract]. J Nucl Med 36(suppl):129, 1995.
42. Moretti JL, Caglar M, Boaziz C, et al: Sequential functional imaging with technetium-99m hexakis-2-methoxyisobutylisonitrile and indium-111 octreotide: Can we predict the response to chemotherapy in small cell lung cancer? Eur J Nucl Med 22:177, 1995.